LYEL logo

LYEL

Lyell Immunopharma Inc.

$11.08
-$0.02(-0.18%)
58
Overall
--
Value
58
Tech
--
Quality
Market Cap
$210.55M
Volume
21.43K
52W Range
$7.65 - $32.00
Target Price
$11.00
Order:

Income Statement

MetricTrendChart
2021
Dec
2022
Dec
2023
Dec
2024
Dec
REVENUE
Total Revenue
$10.7M$84.7M$130.0K$61.0K
Total Revenue
$10.7M$84.7M$130.0K$61.0K
GROSS PROFIT
Gross Profit
$10.7M$84.7M$130.0K$61.0K
OPERATING EXPENSES
Operating Expenses
$225.4M$271.7M$247.1M$358.8M
Research & Development
$138.7M$159.2M$182.9M$258.8M
Research Expense
$138.7M$159.2M$182.9M$171.6M
Selling, General & Administrative
$89.1M$117.3M$67.0M$52.0M
General & Administrative Expenses
$89.1M$117.3M$67.0M$52.0M
Salaries & Wages
--$81.9M$47.1M$33.1M
Depreciation & Amortization
$13.5M$18.0M$20.2M$19.4M
Depreciation & Amortization
$13.5M$18.0M$20.2M$19.4M
Other Operating Expenses
$-2.3M$-4.8M$-2.8M$-3.3M
OPERATING INCOME
Operating income
$-214.8M$-187.1M$-247.0M$-358.8M
EBITDA
$-234.7M$-165.1M$-214.4M$-323.4M
NON-OPERATING ITEMS
Intinc
$1.2M$7.1M$23.5M$24.1M
Net Non-Operating Interest Income/Expense
$1.2M$7.1M$23.5M$24.1M
Gain on Sale of Securities
--$2.9M----
Other Income/Expense
$36.6M$-3.1M$11.1M$59.6M
Other Special Charges
$-161.0K$1.9M$1.8M$4.7M
SPECIAL ITEMS
Restructring And Mn A Income
----$5.5M--
Special Income Charges
----$-5.5M--
Other Impairment Of Capital Assets
$36.4M----$51.3M
PRE-TAX INCOME
EBIT
$-250.2M$-183.1M$-234.6M$-343.0M
Pre-Tax Income
$-250.2M$-183.1M$-234.6M$-343.0M
NET INCOME
Net Income
$-250.2M$-183.1M$-234.6M$-343.0M
Net Income (Continuing Operations)
$-250.2M$-183.1M$-234.6M$-343.0M
Net Income (Discontinued Operations)
$-250.2M$-183.1M$-234.6M$-343.0M
Net Income (Common Stockholders)
$-250.2M$-183.1M$-234.6M$-343.0M
TOTALS
Total Expenses
$225.4M$271.7M$247.1M$358.8M
SHARE & EPS DATA
Average Shares Outstanding
$6.8K$12.4M$12.5M$261.5M
Average Shares Outstanding (Diluted)
$6.8K$12.4M$12.5M$261.5M
Shares Outstanding
$12.3M$12.5M$12.7M$295.2M
Basic EPS
$-36.8$-14.8$-18.6$-1.31
Basic EPS (Continuing Operations)
$-36.8$-14.8$-18.6$-1.31
Diluted EPS
$-36.8$-14.8$-18.6$-1.31
Diluted EPS (Continuing Operations)
$-36.8$-14.8$-18.6$-1.31
OTHER METRICS
Development Expense
------$87.2M
Gain On Sale Of P P E
$308.0K------
Other Gand A
$89.1M$117.3M$67.0M$52.0M
Restruct
----$5.5M--

Financial data is updated quarterly and may not reflect the most recent earnings.

ABCD
1SymbolPriceChangeVol
2LYEL$11.08-0.2%21.43K
3
4
5
6

Get Lyell Immunopharma Inc. Data in Excel

Stream real-time data directly to your spreadsheets

BUY NOW
Stock data provided by MarketXLS.